Previous 10 | Next 10 |
Investigational BCMA CAR-T therapy ciltacabtagene autoleucel (cilta-cel) granted priority review by the U.S. Food and Drug Administration for the treatment of relapsed or refractory multiple myeloma (RRMM) A Marketing Authorisation Application (MAA) was accepted by the Europ...
Shares of Legend Biotech Corporation (NASDAQ:LEGN) traded today at $45.87, eclipsing its 52-week high. So far today approximately 149,000 shares have been exchanged, as compared to an average 30-day volume of 422,000 shares. Legend Biotech Corp is a clinical-stage biopharmaceutical compa...
Legend Biotech Corporation (NASDAQ:LEGN) traded today at a new 52-week high of $44.18. Approximately 149,000 shares have changed hands today, as compared to an average 30-day volume of 393,000 shares. Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the...
NOVATO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced the appointment of Corsee Sander...
Cutting-edge pharma Legend Biotech (NASDAQ: LEGN) burst onto the scene at the 2017 American Society of Clinical Oncology (ASCO) meeting with fantastic early clinical trial results for its multiple myeloma treatment. Now, with even better data in hand after ASCO 2021, the company and...
New Cell Therapy Facility in Belgium Establishes Manufacturing Presence in the European Union New facility builds upon Legend Biotech’s collaboration with Janssen to advance the manufacturing of investigational CAR-T therapy ciltacabtagene autoleucel (cilta-cel), being develo...
A recent regulatory overhaul designed to speed up development and approval of new drugs in China has been welcomed by global pharma giants and local startups alike, aimed at bringing their latest cutting-edge treatments more quickly to Chinese patients. One of the first to seize on th...
ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...
Longer-term results from the Phase 1b/2 CARTITUDE-1 study demonstrated 98 percent overall response rate, 80 percent stringent complete response rate and 66 percent progression free survival rate at 18 months with no new safety signals First results from the CARTITUDE-2 s...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, has announced that the U.S. Food and Drug Administration (FDA) has accepted ...
News, Short Squeeze, Breakout and More Instantly...
Legend Biotech Corporation Company Name:
LEGN Stock Symbol:
NASDAQ Market:
Legend Biotech Corporation Website:
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. During the webcast and confe...
SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from CARTITUDE-4, an ongoing, global randomized, open-label Phase 3 study evaluating the efficacy and sa...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...